Next Article in Journal
Glia Not Neurons: Uncovering Brain Dysmaturation in a Rat Model of Alzheimer’s Disease
Next Article in Special Issue
Complex Syndrome of the Complete Occlusion of the End of the Superior Mesenteric Vein, Opposed with the Stable Gastric Pentadecapeptide BPC 157 in Rats
Previous Article in Journal
Dual Roles of the Activin Signaling Pathway in Pancreatic Cancer
Previous Article in Special Issue
Occluded Superior Mesenteric Artery and Vein. Therapy with the Stable Gastric Pentadecapeptide BPC 157
Article

Stable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal

1
Department of Pharmacology, School of Medicine, University of Zagreb, Salata 11, P.O. Box 916, 10000 Zagreb, Croatia
2
Department of Pathology, School of Medicine, University of Zagreb, Salata 11, P.O. Box 916, 10000 Zagreb, Croatia
*
Authors to whom correspondence should be addressed.
Academic Editor: Alberto Ricci
Biomedicines 2021, 9(7), 822; https://doi.org/10.3390/biomedicines9070822
Received: 14 May 2021 / Revised: 26 June 2021 / Accepted: 12 July 2021 / Published: 15 July 2021
(This article belongs to the Special Issue Frontiers in Pentadecapeptide BPC 157)
Background. Monocrotaline selectively injures the lung’s vascular endothelium and induces pulmonary arterial hypertension. The stable gastric pentadecapeptide BPC 157 acts as a prototype cytoprotective agent that maintains endothelium, and its application may be a novel therapy. Besides, BPC 157 prevents and reverses thrombosis formation, maintains platelet function, alleviates peripheral vascular occlusion disturbances, and has anti-arrhythmic and anti-inflammatory effects. Monocrotaline-induced pulmonary arterial hypertension in rats (wall thickness, total vessel area, heart frequency, QRS axis deviation, QT interval prolongation, increase in right ventricle systolic pressure and bodyweight loss) can be counteracted with early or delayed BPC 157 therapy. Methods and Results. After monocrotaline (80 mg/kg subcutaneously), BPC 157 (10 μg/kg or 10 ng/kg, days 1–14 or days 1–30 (early regimens), or days 14–30 (delayed regimen)) was given once daily intraperitoneally (last application 24 h before sacrifice) or continuously in drinking water until sacrifice (day 14 or 30). Without therapy, the outcome was the full monocrotaline syndrome, marked by right-side heart hypertrophy and massive thickening of the precapillary artery’s smooth muscle layer, clinical deterioration, and sometimes death due to pulmonary hypertension and right-heart failure during the 4th week after monocrotaline injection. With all BPC 157 regimens, monocrotaline-induced pulmonary arterial hypertension (including all disturbed parameters) was counteracted, and consistent beneficial effects were documented during the whole course of the disease. Pulmonary hypertension was not even developed (early regimens) as quickly as the advanced pulmonary hypertension was rapidly attenuated and then completely eliminated (delayed regimen). Conclusions. Thus, pentadecapeptide BPC 157 prevents and counteracts monocrotaline-induced pulmonary arterial hypertension and cor pulmonale in rats. View Full-Text
Keywords: monocrotaline; pentadecapeptide BPC 157; rat; pulmonary arterial hypertension monocrotaline; pentadecapeptide BPC 157; rat; pulmonary arterial hypertension
Show Figures

Figure 1

MDPI and ACS Style

Udovicic, M.; Sever, M.; Kavur, L.; Loncaric, K.; Barisic, I.; Balenovic, D.; Zivanovic Posilovic, G.; Strinic, D.; Uzun, S.; Batelja Vuletic, L.; Sikiric, S.; Skrtic, A.; Drmic, D.; Boban Blagaic, A.; Lovric Bencic, M.; Seiwerth, S.; Sikiric, P. Stable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal. Biomedicines 2021, 9, 822. https://doi.org/10.3390/biomedicines9070822

AMA Style

Udovicic M, Sever M, Kavur L, Loncaric K, Barisic I, Balenovic D, Zivanovic Posilovic G, Strinic D, Uzun S, Batelja Vuletic L, Sikiric S, Skrtic A, Drmic D, Boban Blagaic A, Lovric Bencic M, Seiwerth S, Sikiric P. Stable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal. Biomedicines. 2021; 9(7):822. https://doi.org/10.3390/biomedicines9070822

Chicago/Turabian Style

Udovicic, Mario, Marko Sever, Lovro Kavur, Kristina Loncaric, Ivan Barisic, Diana Balenovic, Gordana Zivanovic Posilovic, Dean Strinic, Sandra Uzun, Lovorka Batelja Vuletic, Suncana Sikiric, Anita Skrtic, Domagoj Drmic, Alenka Boban Blagaic, Martina Lovric Bencic, Sven Seiwerth, and Predrag Sikiric. 2021. "Stable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal" Biomedicines 9, no. 7: 822. https://doi.org/10.3390/biomedicines9070822

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop